Rebamipide - Otsuka Pharmaceutical
Alternative Names: MCT-SR; Mucosta; OPC-12759; OPC-12759E; OPC759; Pramipide; ProamipideLatest Information Update: 20 Nov 2024
Price :
$50 *
At a glance
- Originator Otsuka Pharmaceutical
- Developer Kubota Vision; Otsuka Pharmaceutical
- Class Amino acids; Anti-inflammatories; Antiulcers; Cytoprotectives; Eye disorder therapies; Quinolones; Small molecules
- Mechanism of Action Oxygen radical formation antagonists; Oxygen radical scavengers; Prostaglandin agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Dry eyes; Gastric ulcer; Gastritis
- Phase II Stomatitis
- Discontinued Cancer; Diabetes mellitus; Keratoconjunctivitis; NSAID-induced ulcer; Ulcerative colitis; Xerostomia
Most Recent Events
- 20 Nov 2024 No development reported - Phase-III for Gastritis (In the elderly, In adults) in South Korea (PO) (NCT04189705)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Gastric-ulcer(In volunteers) in South Korea (PO, Controlled release)
- 11 Mar 2021 Otsuka Pharmaceutical completes a phase III clinical trial in Gastritis (In adults, In the elderly) in South Korea (PO, Controlled release) (NCT04189705)